mHSPC VL

Rucaparib in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) A Phase II Study - Emmanuel Antonarakis

Details
Emmanuel Antonarakis introduces the Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH). The aim of this Phase II clinical trial is to find out if the study drug rucaparib leads to lowering of PSA levels in men with metastatic prostate cancer that has not yet been treated with androgen deprivation therapy (also ref...

Treatment Decision Making for the Metastatic Hormone-Sensitive Prostate Cancer Patient Population - Alicia Morgans

Details
Charles Ryan interviews Alicia Morgans on her thoughts about treatment decision making in the metastatic hormone-sensitive prostate cancer (mHSPC) population and changes that are rapidly developing in this area. They review how studies such as CHAARTED, LATITUDE, and STAMPEDE have shaped the current options. The discuss the next sets of data that are expected to further expand treatment options in...

A Review on Practice Informing Prostate Cancer Study Results - Christopher Sweeney

Details
(Length of Conversation: 18 min) Christopher Sweeney and Alicia Morgans review practice informing data released at the ESMO 2018 meeting from the GETUG 12, ERA 223, and STAMPEDE studies. Biographies: Christopher Sweeney, MBBS, Professor of Medicine, Harvard Medical School, Medical Oncologist, Dana-Farber Cancer Institute Alicia Morgans, MD, MPH Related Content: 12-Year Follow-Up of GETUG-12, A Pha...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe